SPIRONOLACTONE ALTERS THE LEVELS OF NEURONAL FUNCTION MARKERS IN AUTISTIC RATS | ||||
| Bulletin of Pharmaceutical Sciences Assiut University | ||||
| Volume 46, Issue 2, December 2023, Page 1301-1312 PDF (1.72 MB) | ||||
| Document Type: Original Article | ||||
| DOI: 10.21608/bfsa.2023.327619 | ||||
 View on SCiNiTO | ||||
| Authors | ||||
Roohi Mirza1; Poonam Sharma1; G T. Kulkarni2; Bhupesh Sharma   1
| ||||
| 1Department of Pharmacology, Amity Institute of Pharmacy, Amity University Uttar Pradesh, Noida, India | ||||
| 2Gokaraju Rangaraju College of Pharmacy, Hyderabad | ||||
| Abstract | ||||
| Autism spectrum disorder (ASD) is a neurodevelopmental disorder that is characterized by repetitive behavior and impairment in social behavior. ASD is a complex disorder with complex etiology that involves multiple genes, environmental factors, and epigenetic mechanism. Many clinical and pre-clinical study have demonstrated the association of propionic acid (PPA) with ASD. This study evaluates the potential effect of spironolactone in PPA induced ASD phenotype. PPA (250 mg/kg, po) was administered to Albino Wistar rats from post-natal day (PND) 21st to 23rd to induce ASD like neurobehavioral and neurobiochemical alterations. Animals were experimented for behavioral (elevated plus maze, three chambered social interaction apparatus, and Y-maze apparatus), biochemical parameters (BDNF, synapsin II), and blood-brain barrier impairment. Post-natal PPA exposure resulted impairment in social behavior, anxiety, and repetitive behavior in animals. Furthermore, PPA exposure caused reduction in the levels of BDNF and synapsin II in rats’ brain. Spironolactone (25 mg/kg and 50 mg/kg) administration was observed to ameliorate post-natal PPA exposed behavioral and biochemical impairments in animals. | ||||
| Keywords | ||||
| Propionic acid; autism; spironolactone; social behavior; repetitive behavior; BDNF; Synapsin | ||||
|
Statistics Article View: 164 PDF Download: 156 |
||||
